Skip to search formSkip to main contentSkip to account menu

Pravastatin

Known as: Pravastatine, [1S-[1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha]]-1,2,6,7,8,8a-Hexahydro-beta,!d,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphthaleneheptanoic Acid, Pravastatin [Chemical/Ingredient] 
A synthetic lipid-lowering agent. Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which… 
National Institutes of Health

Related topics

Related topics

33 relations

Broader (4)

Anticholesteremic AgentsEnzyme InhibitorsHydroxymethylglutaryl-CoA Reductase InhibitorsNaphthalenes

Narrower (11)

CS-514Lin-PravastatinPrareductPravachol
Coronary Artery DiseaseDrug AllergyHepatic Metabolism [PK]Hypercholesterolemia

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Progression of cerebral white matter lesions is not associated with development of depressive symptoms in elderly subjects at risk of cardiovascular disease. The PROSPER Study
Cerebral white matter hyperintensities on magnetic resonance imaging (MRI) scans have been associated with vascular disease and… 
Highly Cited
2003
Highly Cited
2003
Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin
1. The liver is the target organ for the lipid-regulating effect of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A… 
Review
2003
Review
2003
Analytical methods for the quantitative determination of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in biological samples.
Highly Cited
2002
Highly Cited
2002
Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients.
Highly Cited
2002
Highly Cited
2002
Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study.
Highly Cited
2000
Highly Cited
2000
Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death.
Review
2000
Review
2000
Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles.
Review
2000
Review
2000
HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles.
Highly Cited
2000
Highly Cited
2000
Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels.
Highly Cited
1997
Highly Cited
1997
HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)